| Literature DB >> 33916405 |
Sangeeta Chandrashekar1,2, Raman Vijayakumar2, Ramachandran Chelliah1, Eric Banan-Mwine Daliri1, Inamul Hasan Madar3, Ghazala Sultan4, Momna Rubab1,5, Fazle Elahi1, Su-Jung Yeon1, Deog-Hwan Oh1.
Abstract
The study aimed to investigate the antibacterial activity of Mustard (Brassica juncea) and Moringa (Moringa oleifera) leaf extracts and coagulant protein for their potential application in water treatment. Bacterial cell aggregation and growth kinetics studies were employed for thirteen bacterial strains with different concentrations of leaf extracts and coagulant protein. Moringa oleifera leaf extract (MOS) and coagulant protein showed cell aggregation against ten bacterial strains, whereas leaf extract alone showed growth inhibition of five bacterial strains for up to 6 h and five bacterial strains for up to 3 h. Brassica juncea leaf extract (BJS) showed growth inhibition for up to 6 h, and three bacterial strains showed inhibition for up to 3 h. The highest inhibition concentration with 2.5 mg/mL was 19 mm, and furthermore, the minimum inhibitory concentration (MIC) (0.5 mg/mL) and MBC (1.5 mg/mL) were determined to have a higher antibacterial effect for <3 KDa peptides. Based on LCMS analysis, napin was identified in both MOS and BJS; furthermore, the mode of action of napin peptide was determined on lipoprotein X complex (LpxC) and four-chained structured binding protein of bacterial type II topoisomerase (4PLB). The docking analysis has exhibited moderate to potent inhibition with a range of dock score -912.9 Kcal/mol. Thus, it possesses antibacterial-coagulant potential bioactive peptides present in the Moringa oleifera purified protein (MOP) and Brassica juncea purified protein (BJP) that could act as an effective antimicrobial agent to replace currently available antibiotics. The result implies that MOP and Brassica juncea purified coagulant (BJP) proteins may perform a wide degree of antibacterial functions against different pathogens.Entities:
Keywords: Brassica juncea; LCMS; Moringa oleifera; cell aggregation; coagulant protein; growth inhibition; lipoprotein; molecular-docking; napin; topoisomerase
Mesh:
Substances:
Year: 2021 PMID: 33916405 PMCID: PMC8038560 DOI: 10.3390/molecules26072080
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(a) Coagulation activity of Moringa oleifera leaf extract (MOS) and Brassica juncea leaf extract (BJS) and coagulant protein (CP) after 90 min of sedimentation. The crude extracts (CEs) were not diluted, whereas CPs were five times diluted. Kaolin clay without the addition of extract served as a control. Values are expressed as the mean ± standard deviation (n = 3). Different superscripts (a–c) represent significantly different values (p < 0.05). (b) SDS-PAGE of BJS and MOS extracts. Lane 1: Moringa oleifera leaf extract (MOS), 2: Moringa purified coagulant protein (MCP), 3: Marker sigma-aldrich 6.5–66 kDa, 4: Brassica juncea purified coagulant protein (BJP), 5: Brassica juncea leaf extract (BJS).
Figure 2(a) Comparative analysis for aggregation experiments of MOS, BJS (extract), MCP, and BJP (protein) toward thirteen different clinical pathogens. (b) Transmission electron microscopic imaging indicates the antimicrobial activity of purified plant protein (<6.5 KDa) against E. coli (ATCC 25922) and S. aureus (ATCC 19095).
The growth inhibitory activity of Moringa olifera crude extract (MOS), Brassica juncea extract (BJS), Moringa olifera purified protein (MCP), and Brassica juncea purified Protein (MusP) against different clinical pathogens. Antimicrobial activity of plant crude extract and purified coagulant proteins.
| SNo | List of Microorganism | Minimum Inhibitory Concentration (MIC) | |||
|---|---|---|---|---|---|
| Crude | Coagulant Protein | Crude Protein | Coagulant Protein | ||
| 1 |
| 0.01 | 0.02 | 0.05 | 0.09 |
| 2 |
| 0.01 | 0.02 | 0.02 | 0.04 |
| 3 |
| 0.04 | 0.06 | 0.05 | 0.09 |
| 4 |
| 0.01 | 0.02 | 0.05 | 0.08 |
| 5 |
| 0.02 | 0.04 | 0.04 | 0.07 |
| 6 |
| 0.008 | 0.01 | 0.05 | 0.07 |
| 7 |
| 0.01 | 0.02 | 0.05 | 0.09 |
| 8 |
| 0.04 | 0.06 | 0.03 | 0.06 |
| 9 |
| 0.02 | 0.04 | 0.05 | 0.08 |
| 10 |
| 0.01 | 0.02 | 0.05 | 0.08 |
| 11 |
| 0.01 | 0.02 | 0.05 | 0.09 |
| 12 |
| 0.02 | 0.04 | 0.02 | 0.04 |
| 13 |
| 0.01 | 0.02 | 0.05 | 0.08 |
Figure 3Growth inhibition of pathogens based on the different concentrations, further minimum inhibitory concentration was determined in Table 1. (a) MOS extract growth inhibitory activity of S. marcescens, (b) BJS growth inhibitory activity of S. marcescens, (c) MOS extract growth inhibitory activity of S. flexneri, (d) BJS growth inhibitory activity of S. flexneri. Values are expressed as the mean ± standard deviation (n = 3).
Figure 4Regarding molecular docking ligand and protein structure were determined from the respective data bank. (a) Three-dimensional (3D) molecular structure of the structure of napin was determined from (www.rcsb.org/structure/1PNB). (b) Two-dimensional (2D) molecular structure of S.A. gyrase–AM8191 complex was determined from (www.rcsb.org/structure/4PLB). (c) Crystal structure of potent inhibitors of LpxC (treatment of Gram-Negative infection dimensional (3D) Molecular structure was determined from (www.rcsb.org/structure/3U1Y).
Figure 5(a) (i) The interaction analysis between napin (pink) and 3U1Y (Blue) by molecular docking. (ii) The interaction model of complex napin and 3U1Y—the 3D structure of protein complex. (iii) Interfaces and key residues analysis. (iv) Ligplot representation of showing hydrogen and hydrophobic interactions between Pediocin and LipoXc (cell-wall protein) complex. (b) (i) The interaction analysis between napin (pink) and 4plb (Blue) by molecular docking. (ii) The interaction model of complex napin and 4plb—the 3D structure of protein complex. (iii) Interfaces and key residues analysis. (iv) Ligplot representation of showing hydrogen and hydrophobic interactions between Pediocin and 4plb (Topoisomerase peptide) complex.
List of interacting residues between two docked proteins. Interaction type is mentioned as hydrophobic interactions and hydrogen bond interaction between napin with 3U1Y and 4PLB.
|
|
|
|
|
|
|
|
|
| Napin_3u1y | 2768.19 | 25424.35 | 28192.54 | 25088.38 | 3104.16 | −786 | Lowest Energy |
|
|
|
|
|
|
|
| |
| Napin_4plb | 2768.19 | 54046.17 | 56814.36 | 53812.11 | 3002.25 | −912.9 | Lowest Energy |
Strongest Binding: Napin–Lipid2; Weak Binding: Napin–3u1y.
Molecular instructions of napin with compounds with bacterial structural and function proteins (based on LC-ESI-TOF-MS/MS analysis among the 2174 peptide in MOS and 1119 peptide in BJS; the napin peptide sequence similarity was found to be higher and stronger with molecular docking interaction with the cell wall of the Gram-negative bacterial protein (LpxC) and topoisomerase peptide (4PLP)).
| Type of Interactions | Hydrogen | Hydrophobic | ||
|---|---|---|---|---|
|
|
|
|
|
|
|
| GLU 12, GLU 8 | ARG 465, LYS 441, ASP 458, THR 360, GLN 502, LYS 371, TYR 498, ASP 495, ARG 494, GLU 518, HIS 563, LYS 537, ASN 519 | EU 15, GLN 6 | ASP 460,PRO 462, LYS 560, PHE 459, PHE 4922, GLY 491, MET 361, LEU 499, LEU 504 |
|
|
|
|
|
|
|
| PHE 31, PRO 30, GLN 1, GLN 6, GLN 25, GLN 20, CYS 18, LYS 4, GLU 8, CYS 5 | ALA 640, LYS 607, ALA 534, ASN 1010, GLU 1011, SER 1021, ASP 1024, ARG 517, THR 544, THR 594, GLU 599, ARG 601, LYS 502 | GLU 12, ILE 22, PHE 9, LEU 26, GLN 24, TRP 21, PRO 2 | GLY 1341, VAL 1031, MET 1027, ARG 1012, TYR 639, HIS 600, GLN 505, GLU 1020, LEU 603, ALA 602, ALA 509, PRO 542, ILE 539, GLN 541, HIS 501, PRO 598 |
Comparative analysis of antibiotics toward thirteen different clinical pathogens (analysis on the antimicrobial resistance of clinical pathogens (isolated from dysentery patients), which was applied in the study).
| SNo | List of Pathogens | Nucleic Acid Targeting Antibiotic (A) | Cell Wall Targeting Antibiotic (B) | Protein Synthesis Inhibiting Targeting Antibiotic (C) | ||
|---|---|---|---|---|---|---|
| Novobiocin | Clindamycin | Gentamicin | Ampicillin | Vancomycin | ||
| 1 |
| 12.00 ± 0.05 c | 14.00 ± 0.10 b | 16.00 ± 0.05 b | 12.00 ± 0.07 c | 13.00 ± 0.05 c |
| 2 |
| 14.00 ± 0.03 a | - | 17.00 ± 0.02 b | 12.00 ± 0.01 c | 12.00 ± 0.03 c |
| 3 |
| - | - | - | 16.00 ± 0.01 b | 10.00 ± 0.07 c |
| 4 |
| - | - | 13.00 ± 0.05 c | 14.00 ± 0.03 b | 15.00 ± 0.03 b |
| 5 |
| - | - | 15.00 ± 0.03 b | 15.00 ± 0.04 a | 17.00 ± 0.03 b |
| 6 |
| - | 17.00 ± 0.03 b | 16.00 ± 0.03 b | 14.00 ± 0.11 b | |
| 7 |
| - | - | 14.00 ± 0.08 b | 15.00 ± 0.02 b | |
| 8 |
| - | - | 15.00 ± 0.03 b | - | |
| 9 |
| 16.00 ± 0.05 a | 17.00 ± 0.02 a | 12.00 ± 0.03 c | 14.00 ± 0.09 b | 12.00 ± 0.03 c |
| 10 |
| 12.00 ± 0.12 c | 15.00 ± 0.06 a | 15.00 ± 0.03 b | 12.00 ± 0.04 c | 10.00 ± 0.02 c |
| 11 |
| - | - | - | 12.00 ± 0.03 c | 13.00 ± 0.05 c |
| 12 |
| - | - | - | 14.00 ± 0.05 b | 12.00 ± 0.01 c |
| 13 |
| - | 14.00 ± 0.04 b | 14.00 ± 0.03 c | 10.00 ± 0.02 c | 10.00 ± 0.06 c |
- not active, a more sensitive, b moderate sensitive, c less sensitive, Media—tryptic soy agar.
Overall view on the combined effect of coagulation (flocculation of artificial clay–kaolin) and antimicrobial activity (growth inhibition) of Moringa olifera (Moringa) and Brassica juncea (Mustard) leaf extracts toward thirteen different clinical pathogens.
| Sample | List of Pathogens |
|
| ||
|---|---|---|---|---|---|
| Aggregation | Growth Inhibition | Aggregation | Growth Inhibition | ||
| 1 |
| + | + | + | + |
| 2 |
| + | + | + | + |
| 3 |
| + | - | + | - |
| 4 |
| + | + | + | - |
| 5 |
| + | + | + | + |
| 6 |
| + | + | + | - |
| 7 |
| + | + | + | - |
| 8 |
| + | - | - | - |
| 9 |
| + | + | - | - |
| 10 |
| + | - | - | - |
| 11 |
| - | + | + | - |
| 12 |
| - | + | - | + |
| 13 |
| - | + | - | + |